A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP

A PROSPECTIVE MULTICENTER PHASE 2 STUDY OF THE CHEMOTHERAPY-FREE COMBINATION OF POLATUZUMAB VEDOTIN AND GLOFITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WITHIN 12 MONTHS OF R-CHOP TREATMENT

Patients with diffuse large B-cell lymphoma (DLBCL) who are primary refractory to first-line R-CHOP therapy or relapse within 12 months after R-CHOP have a poor prognosis and limited treatment options. Conventional salvage chemotherapy has limited efficacy, and CAR-T cell therapy may be limited by manufacturing time, accessibility, and patient condition. Therefore, an immediately available, chemotherapy-free treatment strategy that may reduce the cumulative toxicity of conventional cytotoxic chemotherapy is needed.

Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that delivers a cytotoxic agent to malignant B cells, and glofitamab is a CD20×CD3 bispecific antibody that activates T cells and induces immune-mediated antitumor activity. The combination of these two agents may provide complementary antitumor effects through direct tumor cell killing and T-cell-mediated immune response.

This single-arm, open-label, phase 2 study will evaluate the efficacy and safety of polatuzumab vedotin in combination with glofitamab in patients with DLBCL who are primary refractory to or relapse within 12 months after first-line R-CHOP therapy. Approximately 47 participants will be enrolled. The primary endpoint is the complete response rate at the end of treatment, as assessed by the investigator according to Lugano 2014 criteria.

Study Overview

• Status: Not yet recruiting
• Conditions: Diffuse Large B-cell Lymphoma
• Intervention / Treatment: Drug: Polatuzumab vedotin, Glofitamab

Detailed Description

This is a multicenter, single-arm, open-label, phase 2 study designed to evaluate the efficacy and safety of polatuzumab vedotin in combination with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL) who are primary refractory to first-line R-CHOP therapy or relapse within 12 months after R-CHOP therapy.

Approximately 47 participants will be enrolled at approximately seven study sites in Korea, allowing for an approximately 10% dropout rate to secure 42 efficacy-evaluable participants. The planned enrollment period is approximately 24 months. Participants will be followed for at least 12 months after the end of treatment, and the total study duration is expected to be approximately 4 years.

Treatment will be administered for a fixed duration of up to 12 cycles, with each cycle defined as 21 days. The treatment period consists of two parts.

Part A includes Cycles 1 through 6, during which participants will receive obinutuzumab pretreatment followed by combination therapy with polatuzumab vedotin and glofitamab. Obinutuzumab 1000 mg will be administered once by intravenous infusion on Cycle 1 Day 1. Polatuzumab vedotin 1.8 mg/kg will be administered by intravenous infusion on Cycle 1 Day 2 and then on Day 1 of each cycle from Cycle 2 through Cycle 6 at 21-day intervals. Glofitamab will be administered using step-up dosing: 2.5 mg by intravenous infusion on Cycle 1 Day 8, 10 mg by intravenous infusion on Cycle 1 Day 15, and 30 mg by intravenous infusion on Day 1 of each cycle from Cycle 2 through Cycle 6.

Part B includes Cycles 7 through 12, during which participants will receive glofitamab monotherapy. Glofitamab 30 mg will be administered by intravenous infusion on Day 1 of each 21-day cycle.

Disease response will be assessed using PET-CT, or contrast-enhanced CT if PET-CT cannot be performed, at Week 9, Week 18, Week 36, and at the end of treatment, based on Cycle 1 Day 1. Response will be evaluated according to Lugano 2014 criteria.

The primary endpoint is the complete response rate at the end of treatment, as assessed by the investigator according to Lugano 2014 criteria. Secondary endpoints include overall response rate, duration of response, progression-free survival, overall survival, duration of complete response, time to first objective response, and safety. Exploratory analyses will evaluate ctDNA-based minimal residual disease and immune cell profiling in relation to clinical response and long-term outcomes.

To reduce the risk of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, risk mitigation measures including obinutuzumab pretreatment, step-up dosing of glofitamab, and premedication will be implemented according to the protocol.

• Study Type: Interventional
• Enrollment (Estimated): 47
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: JIN SEOK KIM, Professor; Phone Number: +82-02-2228-4242; Email: HEMAKIM@yuhs.ac

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Histologically proven DLBCL

2. Relapsed or refractory disease after first-line chemoimmunotherapy containing both rituximab and anthracycline A.Refractory disease defined as no complete remission to first-line therapy; subjects who are intolerant to first-line therapy are excluded

   • Progressive disease (PD) as best response to first-line therapy
   • Stable disease (SD) as best response after at least 4 cycles of first-line therapy
   • Partial response (PR) as best response after at least 6 cycles, and biopsy-proven residual disease or disease B.Relapsed disease defined as complete remission to first-line therapy followed by biopsy- proven disease relapse ≤ 12 months of initiating first-line therapy
3. Signed Informed Consent Form
4. Age ≥ 19 years at the time of signing Informed Consent Form and willingness to comply with study protocol procedures
5. Life expectancy ≥ 12 weeks
6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2
7. At least one bi-dimensionally measurable (≥ 1.5 cm) nodal lesion, or one bi-dimensionally measurable (≥ 1 cm) extranodal lesion, as measured on CT scan
8. Negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test within 7 days prior to enrollment

9. Negative HIV test at screening, with the following exception:

   i.Individuals with a positive HIV test at screening are eligible provided, prior to enrollment, they are stable on antiretroviral therapy, have a CD4 count ≥ 200/µL, and have an undetectable viral load.

10. For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, as defined below:

    i.Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 18 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab, 9 months after the final dose of polatuzumab vedotin, and 3 months after the final dose of tocilizumab (as applicable), whichever is longer. Women must refrain from donating eggs during this same period ii.A female participant is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Per this definition, a female participant with tubal ligation is considered to be of childbearing potential. The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.

    iii.Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

    Hormonal contraceptive methods must be supplemented by a barrier method. iv.The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.

11. For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm, as defined below:

    i.With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 3 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab, 6 months after the final dose of polatuzumab vedotin, or 2 months after the last dose of tocilizumab (as applicable), whichever is longer. Male participants must refrain from donating sperm during this same period.

    ii.The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.

12. Adequate hematologic function (unless due to underlying disease, as established for example, by extensive bone marrow involvement or due to hypersplenism secondary to involvement of the spleen by LBCL per the investigator for which blood product transfusions are permitted) defined as follows:

    • Hemoglobin ≥ 9.0 g/dL without packed RBC transfusion during 7 days before first treatment.
    • ANC ≥1.0x109/L
    • Platelet count ≥75 x 109/L
13. Adequate renal function, defined as measured or estimated creatinine clearance ≥50 mL/min

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

Contraindication to any of the individual components of glofitamab or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products

1. Prior solid organ transplantation
2. Prior treatment with a regimen containing polatuzumab vedotin or glofitamab
3. Prior treatment with systemic immunotherapeutic agents, including but not limited to, radio-immuno-conjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (mAbs) (e.g., anti-cytotoxic T lymphocyte associated protein 4, anti-PD-1, and anti-PD-L1) within 4 weeks or five half-lives of the drug, whichever is shorter
4. Prior use of any monoclonal antibody for the purposes of treating cancer within 3 months of the start of Cycle 1
5. Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1
6. Prior radiotherapy to the mediastinal/pericardial region(Radiotherapy to non-target lesion sites will be permitted.)
7. Current Grade > 1 peripheral neuropathy

8. Corticosteroid use > 50 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control i.Participants receiving corticosteroid treatment with ≤ 50 mg/day of prednisone or equivalent for reasons other than lymphoma symptom control (e.g., rheumatoid arthritis) must be documented to be on a stable dose of at least 4 weeks duration prior to the start of Cycle 1.

   • Corticosteroid therapy for control of cancer symptoms or side effects of prior treatment (e.g., nausea or B-symptoms) is permitted
   • The use of inhaled corticosteroids is permitted.
   • The use of mineralocorticoids for management of orthostatic hypotension is permitted.
   • The use of physiologic doses of corticosteroids for management of adrenal insufficiency is permitted.

   ii.Participants who require lymphoma symptom control during screening may receive steroids in the following manner:

   • Up to 50 mg/day of prednisone or equivalent may be used for lymphoma symptom control during screening, including prior to finalization of staging (not included as part of pre-phase treatment).
   • If glucocorticoid treatment is urgently required at higher doses for lymphoma symptom control prior to the start of study treatment, tumor assessments must be completed prior to initiation of > 30-100 mg/day of prednisone or equivalent. Prednisone > 30-100 mg/day or equivalent may be given for a maximum of 10-14 days as a pre-phase treatment. As part of the pre-phase treatment, vincristine may not be administered.

9. History of other malignancy that could affect compliance with the protocol or interpretation of results:

   i.Participants with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix at any time prior to the study are eligible.

   ii.Participants with any malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for ≤ 2 years prior to enrollment are eligible.

   iii.Participants with low-grade, early-stage prostate cancer (Gleason score 6 or below, Stage 1 or 2) with no requirement for therapy at any time prior to study are eligible.

10. Significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV cardiac disease or Objective Assessment Class C or D, myocardial infarction within the last 3 months prior to the start of Cycle 1, unstable arrhythmias, or unstable angina
11. Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
12. Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease i.Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurological deficits, as judged by the investigator, are allowed.
13. Current or past history of CNS lymphoma
14. Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
15. Current or past history of Waldenström macroglobulinemia
16. History or presence of an abnormal ECG that is clinically significant in the investigator's opinion
17. Patients with known or suspected active infection, or reactivation of a latent infection, whether bacterial, viral (including, but not limited to, SARS-Cov-2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis B, and hepatitis C), fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks of dosing

18. History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents, as follows:

    i.Grade ≥ 3 adverse events with the exception of Grade 3 endocrinopathy managed with replacement therapy.

    ii.Grade 1/2 adverse events that did not resolve to baseline after treatment discontinuation.

19. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis i.Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.

    ii.Participants with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible for this study.

    iii.Participants with controlled Type I diabetes mellitus who are on an insulin regimen are eligible for the study.

    iv.Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible (e.g., participants with psoriatic arthritis are excluded) if all the following conditions are met:

    • Rash covers < 10% of body surface area.
    • Disease is well controlled for the last 12 months and requires only low-potency topical corticosteroids.
20. Clinically significant liver disease, including active viral or other hepatitis or cirrhosis
21. Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment

22. Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):

    • INR or PT >1.5 Xupper limit of normal (ULN) in the absence of therapeutic anticoagulation.
    • PTT or aPTT > 1.5 XULN in the absence of a lupus anticoagulant.
    • Serum AST and ALT ≥ 2.5 XULN
    • Total bilirubin ≥ 1.5XULN Participants with documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0XULN
23. Live, attenuated vaccine within 4 weeks before study treatment infusion on Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study. Live vaccines during the study and until participants B cells recover, are prohibited Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine at any time during the study treatment period.
24. Suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay)
25. Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HBsAg] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
26. Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
27. Participants with a history of progressive multifocal leukoencephalopathy
28. Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 18 months after pretreatment with obinutuzumab or 2 months after the final dose of glofitamab, whichever is longer
29. Positive SARS-CoV-2 test within 7 days prior to enrollment. Rapid antigen test result is also acceptable

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Polatuzumab vedotin, Glofitamab; Participants will receive fixed-duration treatment with polatuzumab vedotin in combination with glofitamab, followed by glofitamab monotherapy. Treatment will be administered in 21-day cycles for up to 12 cycles. In Part A, corresponding to Cycles 1 through 6, participants will receive obinutuzumab pretreatment, polatuzumab vedotin, and glofitamab. In Part B, corresponding to Cycles 7 through 12, participants will receive glofitamab monotherapy.

Drug: Polatuzumab vedotin, Glofitamab; Participants will receive fixed-duration treatment with polatuzumab vedotin in combination with glofitamab. Obinutuzumab 1000 mg will be administered once by intravenous infusion on Cycle 1 Day 1 as pretreatment before glofitamab administration. Polatuzumab vedotin 1.8 mg/kg will be administered by intravenous infusion on Cycle 1 Day 2 and then on Day 1 of each cycle from Cycle 2 through Cycle 6. Glofitamab will be administered by intravenous infusion using step-up dosing: 2.5 mg on Cycle 1 Day 8, 10 mg on Cycle 1 Day 15, and 30 mg on Day 1 of each cycle from Cycle 2 through Cycle 12. Each cycle is 21 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete response rate at the end of treatment	Complete response rate is defined as the proportion of participants who achieve complete response at the end of treatment, as assessed by the investigator according to Lugano 2014 criteria based on PET-CT.	At the end of treatment (EOT), up to approximately 36 weeks after the first dose.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate	EOT ORR is defined as the proportion of participants achieving CR or PR at EOT.	From the first dose through the end of treatment (EOT), up to approximately 36 weeks.
Duration of response	DOR is defined as the time from the first documented objective response to disease progression or death from any cause.	From the first documented objective response until disease progression or death from any cause, assessed when all enrolled participants have completed at least 12 months of follow-up after EOT.
Progression-free survival	PFS is defined as the time from the first dose to disease progression or death from any cause.	From the first dose until disease progression or death from any cause, whichever occurs first, assessed when all enrolled participants have completed at least 12 months of follow-up after EOT.
Overall survival	OS is defined as the time from the first dose to death from any cause.	From the first dose until death from any cause, assessed when all enrolled participants have completed at least 12 months of follow-up after EOT.
Duration of complete response	DOCR is defined as the time from the first documented complete response to disease progression or death from any cause.	From the first documented complete response until disease progression or death from any cause, assessed when all enrolled participants have completed at least 12 months of follow-up after EOT.
Time to first objective response	TFOR is defined as the time from the first dose to the first documented objective response.	From the first dose until the first documented objective response, up to approximately 36 weeks.
Safety	Safety will be assessed based on the incidence, nature, frequency, severity, and timing of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0.	From the first dose through 30 days after the last dose of study treatment.

Collaborators and Investigators

• Sponsor: Yonsei University

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): August 31, 2030
• Study Completion (Estimated): August 31, 2030

Study Registration Dates

• First Submitted: July 6, 2026
• First Submitted That Met QC Criteria: July 12, 2026
• First Posted (Actual): July 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 12, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Diffuse large B-cell lymphoma; Phase 2; Polatuzumab vedotin; Complete response rate; Relapsed or refractory DLBCL; Glofitamab; Lugano 2014
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease Attributes; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma; Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases; Recurrence; Lymphoma, Large B-Cell, Diffuse; polatuzumab vedotin; glofitamab
• Other Study ID Numbers: 4-2026-0678

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No